Introduction {#Sec1}
============

Tumor burden, represented by tumor size and the number of involved lymph nodes, is the most important prognostic factor for breast cancer recurrence \[[@CR1]\],\[[@CR2]\] because advanced-stage tumors are more likely to have distant metastases. In the genomics era, rapid advances in translational research have greatly improved our understanding of breast cancer biology. This work provides us with the tools that can identify intrinsic subtypes of breast cancer and discriminate a prognosis according to subtype \[[@CR3]\], highlighting the clinical availability of tumor biology in breast cancer prognosis \[[@CR4]\],\[[@CR5]\]. These studies provide evidence that small tumors with undesirable biology can lead to a worse prognosis than large tumors with favorable biology. Therefore, to deliver more effective personalized medical treatment to individual patients, there is an increasing need to evaluate cancer with tumor biology integration, as well as simple anatomical staging.

^18^F-fluorodexoyglucose positron emission tomography (FDG-PET) is a useful tool in the prediction of tumor recurrence, as well as for providing relevant anatomical information, because this imaging modality reflects tumor biology well \[[@CR6]\],\[[@CR7]\]. It is one of the new tools that can capture tumor biology without an invasive procedure. The degree of FDG uptake reflects the metabolic characteristics of tumors and can be used as a prognostic factor in various malignancies. In breast cancer, studies have shown the contribution of tumor biology to increased FDG uptake \[[@CR8]\]-\[[@CR10]\] and have demonstrated that FDG uptake is associated with aggressive tumor characteristics \[[@CR11]\],\[[@CR12]\].

As like other molecular markers were compared or integrated with tumor burden, we wondered whether the prognostic power of current clinical parameters improves when the biologic information of FDG-PET is combined with them. In this retrospective study, we evaluated the potential of FDG uptake as a prognostic indicator in breast cancer as compared to, and in combination with, tumor burden.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Between April 2004 and May 2009, 1,053 women consecutively underwent surgery for breast cancer at our institution. Of these 1,053 patients, 835 underwent preoperative FDG-PET as a part of their routine preoperative staging. Patients were excluded on the basis of the following criteria: known bilateral breast cancer (*n* = 31), preoperative chemotherapy (because chemotherapy can affect tumor characteristics related to FDG uptake) (*n* = 94), ductal carcinoma *in situ* (*n* = 135) and distant metastases at initial assessment (*n* = 42). Among these patients, 501 women of interest were identified. Patients missing data for any immunohistochemical marker were excluded (*n* = 3). Patients with an immunohistochemistry (IHC) scores of 2+ for human epidermal growth factor receptor 2 (HER2), but without fluorescence *in situ* hybridization (FISH) results for HER2 amplification, were also excluded (*n* = 2). Data for the remaining 496 patients were entered into the analysis (Figure [1](#Fig1){ref-type="fig"}).Figure 1**CONSORT chart outlining the study plan.** DCIS, Ductal carcinoma *in situ*; FDG-PET, ^18^F-fluorodeoxyglucose positron emission tomography; FISH, Fluorescence *in situ* hybridization; HER2, Human epidermal growth factor receptor 2; IHC Immunohistochemistry.

For the immunohistochemical study of four markers, formalin-fixed, paraffin-embedded tissue sections obtained from the surgical specimens were stained with appropriate antibodies for estrogen receptor (ER) (Novocastra; Leica Microsystems, Newcastle upon Tyne, UK), progesterone receptor (PR) (Novocastra; Leica Microsystems), HER2 (Ventana Medical Systems, Tucson, AZ, USA) and Ki-67 (MIB-1; Dako, Glostrup, Denmark). For HER2 evaluation, membranous staining was graded with a score of 0, 1+, 2+ or 3+ \[[@CR13]\]. HER2 status was considered positive with a score of 3+ and negative with a score of 0 or 1+. Tumors with a score of 2+ were sent for FISH testing performed using the PathVysion HER-2 DNA Probe Kit (Abbott Molecular, Des Plaines, IL, USA).

The staging was performed according to the American Joint Committee on Cancer (AJCC) system \[[@CR14]\]. The Elston-Ellis modification of the Scarff-Bloom-Richardson grading system was used for tumor grading. Adjuvant systemic therapy and/or radiotherapy were administered according to the standard guidelines based on patient age, primary tumor characteristics and axillary lymph node status. Endocrine therapy was given to patients whose tumors were positive for hormone receptor expression. The follow-up protocol included planned regular visits every 6 months, and missed appointments were followed by telephone calls to minimize the number of patients lost to follow-up and improve the accuracy of the survival data. The final update to the clinical database was made in December 2013.

The institutional review board (IRB) of Gangnam Severance Hospital, Yonsei University, Seoul, Korea, approved the study in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The IRB granted a waiver of written documentation of informed consent from all participants because of the retrospective study design.

^18^F-fluorodeoxyglucose positron emission tomography {#Sec4}
-----------------------------------------------------

Prior to undergoing FDG-PET, each patient was asked to fast for a minimum of 8 hours, and blood glucose levels were controlled to \<130 mg/dl. Patients received an intravenous injection of ^18^F-FDG (0.14 MBq) in the arm contralateral to the primary tumor. Sixty minutes after injection of ^18^F-FDG, whole-body emission scans were obtained using a Philips Allegro PET camera (Philips Medical Systems, Cleveland, OH, USA). Scans were obtained with the patient in the supine position with the arms raised. Attenuation-corrected transaxial images were reconstructed with an iterative transmission algorithm (row-action maximum likelihood three-dimensional protocol) using a three-dimensional image filter in a 128 × 128 matrix. For semiquantitative evaluations, maximum standardized uptake value (SUV~max~) was calculated by measuring the ^18^F-FDG absorption by tumors in the region of interest (ROI) using the following equation: SUV~max~ = (maximal radioactivity concentration in the ROI (μCi/g)/injected dose (μCi)/patient's weight (kg)). All FDG-PET scans were reviewed by two nuclear medicine radiologists who were blinded to survival data. SUV~max~ was obtained at the time of the imaging procedure.

Statistical analysis {#Sec5}
--------------------

The cutoff point of SUV~max~ was obtained by using the time-dependent receiver operating characteristic (ROC) curve. Age is presented in the study as median value with a range and was compared by the Mann-Whitney *U* test. Discrete variables were compared by performing a χ^2^ test. The primary endpoint was recurrence-free survival (RFS), which was measured from the date of the first curative surgery to the date of the first tumor recurrence, including locoregional recurrence or distant metastasis or death. Breast cancer--specific survival (BCSS) was measured from the date of the first curative surgery to the date of the last follow-up or until death due to breast cancer during the follow-up period. The Kaplan-Meier method was utilized to estimate RFS or BCSS. Using Harrell c-statistics \[[@CR15]\], the concordance index (*c*-index) was calculated to measure the concordance for time-to event data, in which increasing values between 0.5 and 1.0 indicated improved prediction. The significant prognostic factors associated with RFS were selected based on the *c*-index (Additional file [1](#MOESM1){ref-type="media"}). The Cox proportional hazards regression model was used for multivariable survival analysis. To assess the additional prognostic value of SUV~max~, we used changes in the likelihood ratio values (LR − Δχ^2^) to quantitatively measure the relative amount of information for SUV~max~ compared to the model without SUV~max~. The cutoff value of young age was defined as 35 years in accordance with a previous Korean study \[[@CR16]\]. SPSS version 18 (SPSS, Chicago, IL, USA) and R \[[@CR17]\] were used to perform these analyses. Statistical significance was defined by a *P*-value \<0.05 or a 95% confidence interval (CI).

Results {#Sec6}
=======

Definition of cutoff point for maximum standardized uptake value {#Sec7}
----------------------------------------------------------------

The cutoff point of SUV~max~ was obtained using the time-dependent ROC. The time-dependent ROC curve for SUV~max~ in relation to RFS yielded an area under the curve of 0.673 (95% CI, 0.588 to 0.753) (Additional file [2](#MOESM2){ref-type="media"}). Youden's index was the highest for SUV~max~ of 4.2. Considering the clinical application, we defined the SUV~max~ cutoff as 4.

Patient characteristics {#Sec8}
-----------------------

A total of 496 patients with breast cancer were included in the analysis. The median age of the cohort was 48 years (range, 25-80 years). The median and mean SUV~max~ were 4.3 ± 3.1 and 3.2 (range, 0.3-32.9), respectively. When patients were divided into two groups according to SUV~max~, these groups differed significantly in T stage, N stage, AJCC stage, which represent tumor burden. They also differed in characteristics reflecting tumor biology, including histologic grade, ER, PR, HER2, and Ki67. In considering the distribution of tumor subtypes, the group with high SUV~max~ had a higher rate of luminal B, HER2, and triple-negative subtypes. In contrast, the proportion of patients with the luminal A subtype was relatively low in the group with high SUV~max~ (Table [1](#Tab1){ref-type="table"}). A higher rate of mastectomy was noted in the group with high SUV~max~ (Table [1](#Tab1){ref-type="table"}).Table 1**Baseline characteristics according to maximum standardized uptake values** ^**a**^CharacteristicsAll patientsHigh SUVLow SUV***P*** -value ^b^**Age at diagnosis, yr**0.698Median (range)48 (25 to 80)48 (25 to 79)49 (28 to 80)**Histology**\<0.001Invasive ductal carcinoma416 (83.9)173 (87.8)243 (81.3)Invasive lobular carcinoma22 (4.4)1 (0.5)21 (7.0)Mucinous carcinoma13 (2.6)2 (1.0)11 (3.7)Tubular carcinoma6 (1.2)0 (0.0)6 (2.0)Medullary carcinoma4 (0.8)4 (0.8)0 (0.0)Other invasive carcinoma35 (7.7)17 (8.6)18 (6.0)**T classification**\<0.001T1270 (54.4)68 (34.5)202 (67.6)T2217 (43.8)126 (64.0)91 (30.4)T39 (1.8)3 (1.5)6 (2.0)**N classification**0.016N0329 (66.3)115 (58.4)214 (71.6)N1123 (24.8)59 (29.9)64 (21.4)N230 (6.0)17 (8.6)13 (4.3)N314 (2.8)6 (3.0)8 (2.7)**AJCC stage**\<0.001I200 (40.3)42 (21.3)158 (52.8)II252 (50.8)131 (66.5)121 (40.5)III44 (8.9)24 (12.2)20 (6.7)**Histologic grade** ^**c**^\<0.0011157 (35.0)43 (22.8)114 (44.0)2199 (44.4)78 (41.3)121 (46.7)392 (20.5)68 (36.0)24 (9.3)**ER**0.001Positive304 (61.3)102 (51.8)202 (67.6)Negative192 (38.7)95 (48.2)97 (32.4)**PR**0.005Positive293 (59.1)97 (49.2)196 (65.6)Negative203 (40.9)100 (50.8)103 (34.4)**HER-2** ^**d**^\<0.001Positive127 (25.6)72 (36.5)55 (18.4)Negative369 (74.4)125 (63.5)244 (81.6)**Ki67**\<0.001High102 (20.6)64 (32.5)38 (12.7)Low394 (79.4)133(67.5)261 (87.3)**Subtypes**\<0.001Luminal A257 (51.8)71 (36.0)186 (62.2)Luminal B71 (14.4)39 (19.8)32 (10.7)HER283 (16.7)45 (22.8)38 (12.7)Triple negative85 (17.1)42 (21.3)43 (14.4)**Surgery type**0.043Mastectomy352 (70.9)150 (76.1)202 (67.5)Breast-conserving surgery144 (29.1)47 (24.9)97 (32.5)**Adjuvant chemotherapy**\<0.001Yes347 (70.0)162 (82.2)185 (61.9)No149 (30.0)35 (17.8)114 (38.1)**Adjuvant endocrine therapy**0.001Yes332 (66.9)114 (57.9)218 (72.9)No164 (33.1)83 (42.1)81 (27.1)**Adjuvant radiotherapy**0.915Yes189 (38.1)74 (37.6)115 (38.5)No307 (61.9)123 (62.4)184 (61.5)^a^AJCC, American Joint Committee on Cancer; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; SUV~max~, Maximum standardized uptake value. Data are number of patients (%), except for age. ^b^χ^2^ test. ^c^Data with missing values. ^d^HER2 positivity was defined as a 3+ score on immunohistochemistry or amplification on fluorescence *in situ* hybridization.

Survival outcome {#Sec9}
----------------

At a median follow-up of 6.03 years, tumors had recurred in 40 patients. There were 13 patients with locoregional recurrences, 25 with distant metastases and 2 with combined local recurrence and distant metastases. During the follow-up period, 11 deaths occurred, 8 of which were breast cancer--specific and 3 of which were not breast cancer--specific. The probability of RFS at 6 years was 95.6% for patients with low SUV~max~ and 86.8% for patients with high SUV~max~. High SUV~max~ was significantly predictive of decreased RFS (*P* \< 0.001 by log-rank test) (Figure [2](#Fig2){ref-type="fig"}A). Furthermore, patients with high SUV~max~ showed a reduced BCSS (*P* = 0.007 by log-rank test) (Figure [2](#Fig2){ref-type="fig"}B). When adjusted for age of diagnosis, T stage, nodal status and ER status using the Cox proportional hazards regression model, high SUV~max~ was significantly associated with risk of tumor relapse (hazard ratio, 2.39, 95% CI, 1.20 to 4.76) (Table [2](#Tab2){ref-type="table"}). For this model, the Harrell *c*-index was 0.745. The *c*-index for the multivariate model without SUV~max~ was 0.724. The LR-Δχ^2^ showed a significant improvement of the additional prognostic utility of SUV~max~.Figure 2**Kaplan-Meier plots for disease-free survival and breast cancer--specific survival. (A)** Recurrence-free survival (*P* = 0.001). **(B)** Breast cancer--specific survival (*P* = 0.007). SUV~max~, Maximum standardized uptake value. All *P*-values were calculated by the log-rank test.

###### 

**Multivariate analysis for recurrence-free survival using Cox proportional hazards regression model**

  Factors                        Hazard ratio   95% CI      ***P*** -value   
  ------------------------------ -------------- ----------- ---------------- --
  **Age**                                                   0.144            
                                 \>35 yr        Reference                    
                                 ≤35 yr         1.86        0.81 to 4.25     
  **Tumor size**                                            0.151            
                                 ≤2 cm          Reference                    
                                 \>2 cm         1.63        0.84 to 3.19     
  **Nodal status**                                          0.038            
                                 Negative       Reference                    
                                 Positive       1.93        1.04 to 3.59     
  **Estrogen receptor status**                              0.021            
                                 Positive       Reference                    
                                 Negative       2.19        1.12 to 4.27     
  **HER2 status**                                           0.389            
                                 Negative       Reference                    
                                 Positive       1.33        0.69 to 2.57     
  **SUV** ~**max**~ ^**b**^                                 0.013            
                                 Low (\<4)      Reference                    
                                 High (≥4)      2.39        1.20 to 4.76     

^a^CI, Confidence interval; HER2, Human epidermal growth factor receptor-2; SUV~max~, Maximum standardized uptake value. ^b^*P* = 0.009 and χ^2^ = 25.41 for the comparison with the analysis without SUV~max~ (by the likelihood ratio test).

Prognostic value of a combined maximum standardized uptake values with tumor burden {#Sec10}
-----------------------------------------------------------------------------------

Four patient groups were classified according to SUV~max~ and tumor size: (1) tumor size ≤2 cm and SUV~max~ \<4; (2) tumor size \>2 cm and SUV~max~ \<4; (3) tumor size ≤2 cm and SUV~max~ ≥4; and (4) tumor size \>2 cm and SUV~max~ ≥4. The RFS of the four groups differed significantly (*P* \< 0.001) (Figure [3](#Fig3){ref-type="fig"}A). Within the groups of large tumor size (\>2 cm) and small tumor size (≤2 cm), RFS differed significantly according to the SUV~max~ (*P* = 0.049 and *P* = 0.009, respectively). Conversely, within the groups of high SUV~max~ and low SUV~max~, RFS did not differ according to tumor size (*P* = 0.350 and *P* = 0.096, respectively).Figure 3**Kaplan-Meier plots for recurrence-free survival according to combined factors with tumor burden and SUV** ~**max**~**. (A)** Tumor size (*P* \< 0.001) **(B)** Node status (*P* \< 0.001) **(C)** Stage (*P* = 0.001). SUV~max~, Maximum standardized uptake value. All *P*-values were calculated by the log-rank test.

Furthermore, SUV~max~ was significantly predictive of RFS in combination with nodal status (*P* \< 0.001) (Figure [3](#Fig3){ref-type="fig"}B). Node-positive patients with high SUV~max~ had worse outcomes, whereas node-negative patients with low SUV~max~ had better outcomes. Similarly, SUV~max~ combined with stage was significantly correlated with RFS (*P* = 0.001) (Figure [3](#Fig3){ref-type="fig"}C).

Maximum standardized uptake values in luminal breast cancer {#Sec11}
-----------------------------------------------------------

After the patients were divided into three subtypes (luminal, HER2 or triple-negative), multivariate analysis for RFS was performed in each subtype. In luminal subtypes, which were defined as hormone receptor--positive breast cancer (ER-positive and/or PR-positive), SUV~max~ was found to be a significant prognostic factor for RFS based on multivariate analysis (Table [3](#Tab3){ref-type="table"}). However, in HER2 or triple-negative subtypes, SUV~max~ was not an independent prognostic factor (Additional file [3](#MOESM3){ref-type="media"}).Table 3**Multivariate analysis for recurrence-free survival using Cox proportional hazards regression model in hormone receptor--positive disease** ^**a**^FactorsHazard ratio95% CI***P*** -value**Age**0.001\>35 yrReference≤35 yr6.612.23 to 19.57**Tumor size**0.706≤2 cmReference\>2 cm0.8150.28 to 2.35**Nodal status**0.451NegativeReferencePositive1.490.53 to 4.21**HER2 status**0.277NegativeReferencePositive1.870.61 to 5.77**SUV** ~**max**~0.033Low (\<4)ReferenceHigh (≥4)3.561.11 to 11.41^a^CI, Confidence interval; HER2, Human epidermal growth factor receptor 2; SUV~max~, Maximum standardized uptake value.

The prognostic value of SUV~max~ combined with tumor burden was also assessed in hormone receptor--positive breast cancer. When the patients were classified into four groups according to both combined factors, RFS differed significantly (*P* \< 0.001) (Figure [4](#Fig4){ref-type="fig"}A). There was no difference in RFS when patients were stratified by tumor size within the groups with high SUV~max~ and low SUV~max~ (*P* = 0.950 and *P* = 0.688, respectively). However, within the groups with small tumor sizes (≤2 cm), a significantly reduced RFS was found in patients with high SUV~max~ (*P* = 0.044). In patients with large tumor sizes (\>2 cm), RFS did not differ significantly according to SUV~max~ (*P* = 0.065), possibly due to the limited number of patients (*n* = 122).Figure 4**Kaplan-Meier plots for recurrence-free survival according to a combined factor that includes both tumor burden and SUV** ~**max**~**in hormone receptor-positive cancer. (A)** Tumor size (*P* = 0.028) **(B)** Node status (*P* = 0.006) **(C)** Stage (*P* = 0.029). SUV~max~, Maximum standardized uptake value. All *P*-values were calculated by the log-rank test.

In luminal breast cancer, SUV~max~ was still predictive of RFS in combination with nodal status (negative vs. positive) and stage (I vs. II and III) (*P* \< 0.006 and *P* = 0.029, respectively) (Figure [4](#Fig4){ref-type="fig"}B and [4](#Fig4){ref-type="fig"}C).

Discussion {#Sec12}
==========

The results of our study demonstrate the ability of SUV~max~ to predict clinical outcomes in a large cohort of breast cancer patients who underwent FDG-PET. SUV~max~ carried independent prognostic significance in multivariate analysis for prediction of tumor relapse. Attempts to validate FDG uptake as a prognostic indicator in breast cancer have been made in previous studies \[[@CR18]\]-\[[@CR20]\]. However, failure to be validated as an independent prognostic factor \[[@CR18]\], small number of patients \[[@CR19]\] and analysis based on a web-accessible risk-assessment model (Adjuvant! Online) \[[@CR20]\] were limitations. Despite these limitations, those studies provided evidence that that FDG uptake has potential as a prognostic marker in breast cancer, which seems reasonable because tumors with increased glucose uptake show aggressive tumor behaviors and high proliferative propensities \[[@CR8]\]-\[[@CR10]\]. Other studies have consistently shown that breast cancer with a high SUV~max~ is associated with ER negativity, high histologic grade, high Ki67 and the triple-negative subtype \[[@CR10]\]-\[[@CR12]\], which is consistent with our data (Table [1](#Tab1){ref-type="table"}). In support of the clinical significance of tumor biology--associated glucose metabolism are recent studies showing that several signaling pathways implicated in cell proliferation and tumor progression also regulate metabolic pathways \[[@CR21]\]-\[[@CR24]\].

Particularly in the survival analyses using a combined factor with SUV~max~ and tumor burden, SUV~max~ showed a superior prediction of RFS in breast cancer compared with clinical tumor load. After four groups were formed using SUV~max~ and tumor size, within the groups with high or low SUV~max~, tumor size did not provide additional prognostic differentiation (Figure [3](#Fig3){ref-type="fig"}A). However, within the groups with large or small tumor size, SUV~max~ improved the prediction of RFS. Similar results were seen when SUV~max~ was combined with nodal status or AJCC stage (Figures [3](#Fig3){ref-type="fig"}B and [3](#Fig3){ref-type="fig"}C). These findings suggest that when tumor biology is considered in addition to clinical tumor burden, prediction of breast cancer prognosis can be improved. SUV~max~ could provide powerful prognostic information about tumor relapse that is superior to considering only tumor burden, similar to the contribution of molecular subtype.

There are established molecular predictors reflecting tumor biology and predicting prognosis in breast cancer. Although the reason that the multigene assays are actively utilized for ER-positive disease has not been fully clarified, authors of meta-analyses of various multigene breast cancer signatures concluded that the prognostic values of the signatures are comparable when evaluated in hormone receptor--positive breast cancers, presumably due to the fact that the proliferation modules within these diverse gene signatures are a common driving force behind their overall prognostic performance \[[@CR25]\],\[[@CR26]\]. By contrast, hormone receptor--negative breast cancers are more proliferative and are usually classified as high risk or are not the appropriate target population for these prognostic signatures \[[@CR25]\],\[[@CR26]\]. In the same context, our results show that the prognostic significance of SUV~max~ is distinct for luminal tumors (Table [3](#Tab3){ref-type="table"}, Figure [4](#Fig4){ref-type="fig"}).

Furthermore, the mean SUV~max~ for the luminal subtype was the lowest, whereas the values for the HER2 and triple-negative subtypes were comparatively higher (Additional file [4](#MOESM4){ref-type="media"}). This finding is concordant with previous reports comparing SUV~max~ between the IHC-defined subtypes \[[@CR27]\]. It seems reasonable that HER2-positive or triple-negative tumors would show increased accumulation of FDG, because these tumors have an aggressive phenotype and are associated with a high rate of proliferation, high Ki67 concentration and high histologic grades. These associations between aggressive markers and high SUV~max~ were concordantly observed in our study (Table [1](#Tab1){ref-type="table"}). Because HER2-positive or triple-negative tumors generally show high SUV~max~, this may also lead to a reduced prognostic significance of SUV~max~ in these kinds of tumors.

We acknowledge several limitations inherent in our study's retrospective design. We were unable to control for variations in adjuvant therapy that may have influenced survival outcomes. Compared to the low SUV~max~ group, the patients in the high SUV~max~ group received more chemotherapy and less endocrine therapy, likely because they had more advanced stage disease and ER negativity. The cutoff point for SUV~max~ defined within a single cohort also needs to be validated in an external cohort. However, there was not a significant difference in the number of patients who received radiation treatment between the high SUV~max~ group and the low SUV~max~ group. There was also no survival difference between patients who received adjuvant chemotherapy or radiotherapy (Additional file [1](#MOESM1){ref-type="media"}).

Conclusions {#Sec13}
===========

Our study highlights the prognostic value of FDG-PET in predicting tumor relapse for breast cancer patients. We provide evidence supporting the potential utility of FDG-PET in combination with clinical tumor burden for the assessment of prognosis as well as evaluation of tumor location in patients with breast cancer. These results lay the groundwork for future studies on the prognostic implication of SUV~max~ for breast cancer treatment.
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